Examining Pathological Effects of Hepatic Inflammation after Traumatic Spinal Cord Injury by Alfredo, Anthony N.
  
 
 
 
 
 
Examining Pathological Effects of Hepatic Inflammation after Traumatic Spinal Cord Injury  
 
Research Thesis 
 
Presented in Partial Fulfillment of the Requirements for Graduation “with Research 
Distinction in Neuroscience” in the undergraduate colleges of The Ohio State University 
 
by 
Anthony N. Alfredo 
 
The Ohio State University 
May 2016 
 
Project Advisor: Dr. Dana M. McTigue, Department of Neuroscience 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Table of Contents 
Abstract…………………………………………………………………………………………………….………....3 
List of Figures…………………………………………………………………………………………………...….4 
Introduction………………………………………………………………………………………………………...5 
Background…………………………………………………………………………………………………………6 
Methods………………………………………………………………………………………………………….…...9 
Results……………………………………………………………………………………………………………..….11 
Discussion…………………………………………………………………………………………………………...19 
References………………………..................................................................................................................25 
Acknowledgements………………………………………………………………………………………….…..28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abstract 
Sensory and motor functions of the body are regulated by the spinal cord, and traumatic 
spinal cord injury (SCI) permanently impairs these basic functions.  The long term 
consequences of SCI include chronic medical conditions altering each patient’s health and 
quality of life.  In addition to the loss of proper sensory and motor function, injury to the 
spinal cord disrupts homeostasis of directly innervated peripheral organs such as the liver.  
Previously our lab showed that chronic pathological changes in the liver following SCI 
include enhanced lipid deposition and activation of resident liver macrophages called 
Kupffer cells (KCs) leading to chronic hepatic inflammation.  Interestingly, after SCI the 
hepatic inflammatory response precedes intraspinal inflammation, and some reports 
suggest hepatic inflammation leads to exacerbated spinal cord lesion pathology.  However, 
the ability of hepatic inflammation to alter chronic SCI outcomes has never been tested.  
Therefore, the current study examines the effects of exacerbated or attenuated liver 
inflammation after SCI.  Liver inflammation was induced using a total bile duct ligation 
(BDL) model in a “gain of function” experiment to upregulate KC-mediated inflammation in 
the liver prior and subsequent to a mid-thoracic SCI.  Liver tissue showed an upregulation 
of cytokine mRNA expression, KC activation, fibrosis, and lipid deposition at 28 days post-
SCI when BDL preceded SCI compared to naïve and BDL Sham-operated animals.  This 
reveals that injury to the spinal cord exacerbated the effects of BDL on liver pathology.  
However, no significant changes in spinal cord lesion size or immune activation were 
observed between the groups.  A “loss of function” experiment showed depletion of KCs 
using gadolinium chloride (GdCl3) occurs within 48 hours after injection.  This model will 
be used to test if KC depletion improves outcomes after SCI.  These studies support the link 
between hepatic and CNS inflammation and open the door for new therapeutic targets to 
improve quality of patient health and recovery in a clinical SCI setting. 
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Introduction 
A lifelong condition affecting the lives of thousands across the United States 
annually, spinal cord injury (SCI) is a traumatic neurological impairment that significantly 
reduces health and quality of life for patients.  An estimated 10 to 40 individuals per million 
in the developed world are affected by SCI with 276,000 patients in the US alone1–3.  
Immediately following SCI the spinal cord tissue which survives the injury becomes largely 
at risk of secondary damage caused by neuroinflammatory mechanisms4.  The spinal cord 
innervates the peripheral organs of the body, and secondary damage to the cord leads to 
chronic dysfunction due in part to the vast repertoire of infiltrating leukocytes across the 
damaged blood-spinal cord barrier4–7.  The destruction of spinal tissue can lead to chronic 
health impairments aside from paralysis, including bladder infections, bowel dysregulation, 
and irregular respiratory and cardiac function2.  Although the initial impact that displaces 
and injures the spinal cord tissue is substantial, there is also an intense inflammatory 
response ravaging the body.  Inflammation after SCI upregulates the release of pro-
inflammatory molecules and leukocytes into peripheral tissues, the circulation, and spinal 
cord itself4,5.  Previous studies from our laboratory indicated that the liver, which is a 
critical immune and metabolic organ, is negatively affected by SCI leading to elevated lipid 
deposition and activation of Kupffer Cells (KCs), the resident macrophages of the liver5,8.  
The liver is a principle, visceral immune organ involved in the inflammatory response after 
central nervous system (CNS) injury, and drives the acute phase response (APR) that 
follows immediately9–11.  That being said, relatively few studies examine the interactions 
between the liver and spinal cord after CNS injury—in particular the potential concomitant 
role of hepatic inflammation exacerbating SCI lesion pathology and peripheral deficits.  
Therefore, the goal of the current study is to assess the effects of induced hepatic 
inflammation on outcomes following traumatic SCI by way of “gain of function” and “loss of 
function” studies. 
Hepatic and CNS inflammation are two distinct conditions increasingly studied in 
conjunction.  As previously discussed, recent findings corroborate the CNS inflammatory 
response is potentiated by the liver’s upregulation of the hepatic APR after SCI.  The APR is 
an early reaction in an organism to a stimulus such as infection, necrosis, or trauma9.  The 
hepatic APR induces an array of changes in the body including upregulation of leukocytes, 
fever, and changes in levels of pro-inflammatory cytokines, chemokines, and 
glucocorticoids.  Though these inflammatory mediators facilitate damage caused by the 
APR, the theoretical purpose of this reaction is to promote a return to homeostasis by 
promoting tissue repair.  Conversely, in the context of SCI, upregulation of hepatic 
cytokines like tumor necrosis factor (TNFα) and interleukin-1 beta (IL-1β) leads to 
enhanced leukocytosis in the bone marrow and the distribution of newly generated 
immune cells rapidly (~30 minutes) into the liver parenchyma as well as other peripheral 
organs6.  This response most likely contributes to the development of multiorgan 
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dysfunction syndrome (MODS), systemic inflammatory response syndrome (SIRS), and 
inevitably metabolic syndrome in chronic SCI patients5,6,12.  This is relevant to clinical SCI 
patients as metabolic syndrome affects organs such as the liver and their lifestyle as a 
result.  Indeed, the APR of the liver not only affects the spinal cord following trauma, but 
also contributes to the exacerbation of peripheral organ dysregulation.   
Kupffer cells in the liver contribute to the intensity of the hepatic APR preceding 
CNS injuries8,13.  These resident mononuclear cells play a role in the phagocytosis of debris 
and, more importantly, serve as a major site of pro-inflammatory cytokine synthesis14 and 
aid in the recruitment of peripheral monocytes to the parenchyma15.  The downstream 
effects of enhanced hepatic immune cell function and inflammation were explored 
supplementary to brain injury10,11, and the results showed an exacerbated CNS pathology 
due to enhanced synthesis of hepatic chemokines and consequently leukocyte recruitment.  
Some reports suggest that the lesion pathology of the injured spinal cord may be 
exacerbated by initial liver inflammation preceding intraspinal inflammation5,16.  To 
effectively understand the relationship between lesion pathology and the immune 
response of the liver, it is essential to study both of these reactions jointly.   Investigating 
the effects of heightened inflammation of the liver as well as the attenuation of the APR 
post-SCI can provide insight on the immune mechanisms leading to chronic injury 
sequelae.  Establishing a better understanding of the secondary injury response will 
provide vital information for future work and possibly lead to novel therapeutic strategies 
to reduce lesioned tissue and improve quality of life by attenuating peripheral injuries and 
complications.  
Background 
 Trauma to the spinal cord exhibits distinct pathological responses following the 
primary injury.  As discussed before, the milieu of the injured spinal cord is significantly 
different in appearance when juxtaposed to the CNS of a healthy individual.    The two 
branches of the nervous system—central and peripheral—communicate as peripheral 
nerves extending from the spinal cord directly innervate viscera and the muscles of the 
body.  This transmission of information is disrupted by traumatic events causing SCI and 
after effects including bleeding, edema, activation of neuroglia, cytokine synthesis, and 
destruction of the blood-spinal cord barrier (BSCB)2,17,18.  The lesioned spinal tissue 
resulting from the mechanical trauma is dysfunctional and can no longer maintain 
homeostasis with the innervated periphery.   Loss of the blood-spinal cord barrier occurs in 
part by extravasation of leukocytes.  These blood-borne immune cells along with neuroglia 
attempt to prevent further histological damage by sealing off lacerated tissue to form the 
glial scar around the lesion epicenter19.  The regrowth of lesioned axons is hindered by this 
scarring while demyelination and axonal injury from activated resident microglia and 
recruited macrophages further worsen post-traumatic secondary damage17.  Long term 
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absence of proper autonomic control from the spinal cord is detrimental to visceral 
organs20, in particular to the liver.  CNS control of the liver is mediated by sympathetic 
splanchnic nerves originating from level T7-T12 in the intermediolateral cell column of the 
spinal cord and from descending parasympathetic pathways in the brainstem.  Spinal cord 
injury disrupts the normal propagation of signals from these autonomic pathways and can 
inhibit appropriate liver activity21,22.  The dysfunction of the liver can be augmented further 
by the heightened immune response after injury.  The purpose of the hepatic APR following 
SCI is to regain a homeostatic balance by attenuating the dysregulation of the liver, yet its 
upregulation could contribute to the limited repair and exacerbate pathological changes in 
the SCI lesion.  While enabling SCI patients to walk again is the main objective in many 
spinal cord injury research projects, the sequelae that persist chronically such as 
autonomic dysfunction and complications or failure of metabolic, cardiovascular, and renal 
systems are given little attention yet contribute to patient mortality at a much higher 
rate1,20.  These impairments are certainly not the primary focus of most studies, but are 
important inquiries that receive little attention in the SCI paradigm. 
Previous findings from our laboratory have established that injury to the spinal cord 
induces pathological changes in the liver including enhanced lipid deposition, droplet size, 
chronic macrophage activation, and pro-inflammatory cytokine mRNA expression.  Patients 
with spinal cord injuries are 43% more likely to show signs of nonalcoholic fatty liver 
disease (NAFLD) when compared to healthy individuals5.  NAFLD essentially is observed as 
the hepatic manifestation of metabolic syndrome in chronic SCI patients23.  Changes in lipid 
expression and inflammation in hepatic tissue after SCI can also lead to symptoms that are 
consistent with the advanced form of NAFLD known as nonalcoholic steatohepatitis 
(NASH) and proceeds to enhanced fibrosis, cirrhosis, and loss of regenerative capabilities 
in hepatic tissue5.  A culprit of the aforementioned conditions is activated Kupffer cells that 
secrete cytokines like TNFα and concordantly hinder hepatocyte lipid metabolism24.  These 
changes in the liver after SCI are detrimental, and current data show metabolic problems 
are contributing to mortality an increasing rate in clinical cases1.  
The liver and CNS are immunologically linked in the context of injury, and 
experimental hepatic inflammation activates microglia even in the non-injured CNS12.  
Subsequent to SCI, hepatocytes and Kupffer cells promote the acute inflammatory response 
by secreting cytokines and acute phase proteins into the bloodstream6,8.  As cytokines are 
released into the circulation, the upregulation of leukocyte production in primary lymphoid 
tissue such as the bone marrow may drive increased immune cell recruitment to the spinal 
cord lesion epicenter.  One group determined that levels of hepatic chemokines CCL-2 and 
CXCL-1 were observed in the blood as early as 2h and peaked at 4h after spinal cord 
compression injury11.  The enhancement of the hepatic APR following injury in the spinal 
cord therefore could potentially exacerbate spinal inflammation which can feedback and 
produce further inflammation in the liver.  In metabolic syndrome manifesting post-SCI, the 
liver perpetuates the deposition of lipids and cytokine synthesis while simultaneously 
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being damaged by inflammation resulting from these molecular events5.  Therefore, spinal 
cord injury induces pathological changes in the liver and significantly disrupts proper 
metabolic function.  Still in question however is what effect does changing hepatic 
inflammation, either through a “gain of function” experiment by induction of inflammation 
or a “loss of function” experiment attenuating inflammation, cause in SCI lesion pathology, 
peripheral immune activation, and functional recovery. 
Preliminary data collected by our group observed the effects of induced hepatic 
inflammation on outcomes following spinal cord injury.  We chose to employ the bile duct 
ligation (BDL) model to efficiently produce sustained, chronic hepatic inflammation caused 
by prolonged cholestasis. Cholestasis-induced inflammation enhances Kupffer cell 
activation, which induces acute phase protein production and cytokine synthesis in the 
inflamed liver, is observed in injuries of multiple etiologies12,14,25,26.  Accumulation of bile 
acids in the biliary tract leads to irreversible fibrosis from proliferating stellate cells and 
substantial inflammatory damage to the liver tissue27.  Hepatocytes and Kupffer cells 
exacerbate this damage by triggering the production of inflammatory mediators such as 
cytokines, chemokines, and adhesion molecules15.  Our work showed enhanced pro-
inflammatory gene expression was evident after 5d following BDL in rats.   Hepatic 
macrophage expression and changes in lipid deposition around vasculature of the inflamed 
liver occurs after bile duct ligation and SCI.  Interestingly in the spinal cord, spared tissue 
varied among experimental groups with the BDL and SCI group having the least amount of 
spared tissue and the most pronounced macrophage activation in the lesion epicenter (data 
not shown).  Indeed, induced hepatic inflammation could exacerbate intraspinal 
inflammation and the NAFLD/NASH-like presentation in the liver after SCI as previously 
described5.  This experimental “gain of function” in the liver can potentially affect lesioned 
spinal tissue in a feed-forward manner as well as incur further pathology to hepatic tissue. 
Conversely, "loss of function" experiments that attenuate liver inflammation prior to 
SCI will be performed with the aim of dampening chronic peripheral impairments and 
neuroinflammatory responses.  Gadolinium chloride (GdCl3) is a compound widely used to 
deplete the liver Kupffer cells and inhibit phagocytosis and cytokine production thereby 
reducing exaggerated, KC-mediated inflammation14,28,29.  Attenuation of the KC response in 
the initial hours following SCI may protect the spinal cord via reduced acute phase 
inflammation from the liver.  Indeed, Kupffer cell activity contributes to the number of 
leukocytes recruited to the injured spinal cord and essentially facilitates secondary damage 
occurring immediately afterward10,11.    The use of GdCl3 also stimulates a reduction in the 
fibrosis indicative of liver injury and enhances hepatic tissue regeneration by inhibiting 
these macrophages29,30.  Prevention of Kupffer cell activation also hinders steatosis of the 
liver by sparing hepatocytes, promoting lipid metabolism31 and reversing NAFLD/NASH32.  
This could potentially prevent pathological changes in the liver in chronic SCI.  It is 
essential to study the opposite effects of liver inflammation as a preventative measure to 
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reduce the sequelae of SCI such as NASH and possibly preclude inflammation and 
secondary damage to the spinal cord itself.       
The current investigation will expand the examination of negative effects of induced 
inflammation with both histological and molecular analyses in the liver during the chronic 
phase of injury.  These “gain of function” studies will explore changes in liver lipid 
deposition and spared tissue seen following spinal cord injury as well as hepatic and CNS 
macrophage expression.  In addition, we will determine if induced hepatic inflammation 
prior to mid-thoracic SCI worsens outcomes.  The outcome after selective depletion of 
Kupffer cells in SCI using GdCl3 injections in a “loss of function” study will determine if the 
immune response of the liver is attenuated and thereby lessens intraspinal pathology.  The 
link between hepatic and spinal cord inflammation after injury potentially has clinical 
relevance if attenuation of the hepatic APR is neuroprotective post-SCI.  Collectively, these 
studies will contribute to and improve our understanding of liver inflammation in the 
context of spinal cord injury and its peripheral consequences in the chronic injury phase.  
Methods 
 
Bile Duct Ligation 
 
All procedures were approved for use by the IACUC and followed set standards established 
by the NIH and The Ohio State University animal care guidelines.  Total bile duct ligation 
(BDL) surgery was performed on female Sprague-Dawley rats to model biliary acid 
accumulation and presentation of hepatic inflammation due to chronic cholestasis.    Rats 
(200-300 g; Harlan, Houston, TX) were anesthetized by an intraperitoneal injection of a 
solution of ketamine (80 mg/kg) and xylazine (10 mg/kg) and underwent a single ligation 
of the common bile duct or sham surgery.  The abdominal cavity was opened, and the bile 
duct was exposed and ligated with a single suture superior to the duodenum.  Sham 
surgeries exposed the bile duct only.  The abdominal cavity was then stapled closed and the 
animals were allowed to recover in warm cages.  The animal weights were monitored daily 
and any rats that lost more than 15% of their body weight were sacrificed.  Typically the 
rats exhibited jaundiced skin and discolored urine and feces as early as 3 days post-BDL 
until the end of the experiment. 
Spinal Cord Injury Methodology  
Spinal cord contusion was performed on all animals as a clinically relevant model for SCI.  
At 5 days post-BDL, animals were anesthetized using ketamine and xylazine in the same 
way as the bile duct surgery.  A dorsal laminectomy was performed at level 8 of thoracic 
vertebrae (T8).   Spinal contusion injuries were administered using the Infinite Horizons 
device (Precision Systems and Instrumentation) at 200 kD of force.  Back muscles were 
sutured and the skin was closed with wound clips.  Rats recovered in warm cages after 
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closing the injury site and received 5 mL of saline solution by subcutaneous administration.  
Rat bladders were expressed twice daily and the animals were hydrated with daily 
subcutaneous 0.9% saline for the duration of the experiment after SCI. 
Tissue Extraction and Preparation 
 
Rats were sacrificed at 28 days post-BDL/23 days post-SCI. Fresh liver samples were 
collected from the right medial lobe and cut into 0.5g pieces that were flash frozen in liquid 
nitrogen.  The rats were then perfused with 4% paraformaldehyde (PFA) in 0.1 M 
phosphate buffer solution (PBS).  The tissue was fixed for analysis as the PFA stabilized the 
samples by cross-linked polymerization.  Liver and spinal cord tissue was removed and 
post-fixed in 4% PFA for 2 hours and transferred to 0.2 M phosphate buffer (PB) overnight.  
Samples then were removed from PB and cryoprotected for 2-3 days in 30% sucrose 
solution.  Fixed liver and spinal cord samples were then frozen on dry ice and blocked 
using optimal cutting temperature (OCT) solution. Both the spinal cord and liver tissue 
were sliced in a cryostat and mounted on slides (Superfrost Plus Slides, Fisher Scientific) at 
10 and 20 μm, respectively.  The tissue was cut at -20°C and slides were stored at this 
temperature prior to immunohistochemistry (IHC) analysis. 
Gadolinium Chloride Administration 
Kupffer Cells numbers were reduced in a separate cohort of female, 250g Sprague Dawley 
rats in order to decrease inflammation of the liver.  Animals were anesthetized using 
isoflurane (5%) and 1 mL of gadolinium chloride (10 mg/kg) dissolved in 0.9% saline or 
vehicle was injected and via the lateral tail vein.  Rats were sacrificed and perfused 48 
hours post-injection and tissue samples were collected as previously described. 
Liver and Spinal Cord Histological Analysis 
IHC was performed on liver and spinal cord tissue to assess local and peripheral effects of 
Kupffer Cell-mediated inflammation.  OX42 (CD11b) antibody (Serotec, MCA275, 1:2000) 
was used to visualize liver macrophages and activated macrophages and microglia in the 
spinal cord.  Spinal cord sections collected 0.5 cm rostral and caudal to the lesion epicenter 
were stained with Neurofilament antibody (DSHB, RT97, 1:2000) and Eriochrome Cyanine 
to visualize and differentiate axonal structure and white matter, respectively.  Oil Red O 
staining was used to assess the deposition and accumulation of lipid molecules in hepatic 
tissue.  Masson’s Trichrome staining was used to visualize changes in liver 
cytoarchitecture.  Slides for all stains were dehydrated using ethanol and organic solvent 
(Histoclear) and covered with glass held by Permount (Thermo Scientific).  
Tissue Analysis and Quantification 
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Quantification of all histological protocols was performed by a blinded investigator with 
MCID imaging software (Imaging Research Inc.).  Optimal sections of liver tissue were 
randomly selected from each group.  The proportional area of CD11b+ immunoreactivity 
was quantified from 4-6 random fields per section and dividing the area of anti-CD11b 
stain by the total tissue area.  Oil Red O was also quantified in this way dividing the area of 
Oil Red O+ stain by hepatocyte area.  The injury epicenter was identified with EC/NF 
stained spinal cord sections and analysis of spared tissue and OX42+ 
macrophages/microglia were quantified at the lesion epicenter and in 9 sections spaced 
200 μm rostral and caudal to the epicenter.  
Analysis of Gene Expression 
Frozen liver tissue was homogenized in Trizol Reagent (15596018, Life Technologies) to 
preserve nucleic acids.  Samples were then frozen at -80 °C until assay analysis.  RNA was 
isolated by a standard extraction protocol using chloroform/phenol5,33.  The purity of all 
samples was assessed prior to amplification using microdrop spectrophotometry.  The 
extracted RNA was then synthesized into cDNA using Superscript III reverse transcriptase 
(Invitrogen) according to the manufacturer’s instructions.  Expression of specific genes 
adherent to studies in forthcoming sections were assessed through the use of the 
quantitative Real Time Polymerase Chain Reaction (Applied Biosystems).  Each qPCR 
reaction used 100 ng of cDNA with QuantiTec primers for inflammatory genes (TNFα, 
CD68, CD11b, IL-1α, IL-1β) and SYBR green for detection.  The amplification of each sample 
was normalized using Quantum RNA18S (Applied Biosystems) gene expression as a control 
standard.  Analysis of the relative mRNA expression in each sample was determined by 
using the ΔΔCT method34. 
Statistical Analysis of Data 
Analysis was performed by statistical software (GraphPad Prism, San Diego, CA) using 
ANOVA tests and post-hoc analysis to determine statistical significance.  Minimum level of 
significance was set at a p-value less than 0.05.  The Q-test for statistical outliers was 
utilized to confirm outliers in the data. 
Results 
Bile duct ligation acutely increases pro-inflammatory cytokine gene expression in the liver 
We first set out to examine the effects of BDL surgery on the expression of pro-
inflammatory genes, namely TNFα, IL-1β, CD11b, and CD68, at acute time points. TNFα and 
IL-1β are typical hallmarks in liver metabolic diseases and pathology after spinal cord 
injury5,7,20,32,35,36.  Ligation of the common bile duct created a trending increase in all four 
cytokine genes examined at 1, 3, and 5 days post-BDL (Fig. 1).  The levels of TNFα, IL-1β, 
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Figure 1: Elevated cytokine expression after acute ligation of the common bile duct. (A) Liver tumor necrosis 
factor (TNFα), (B) interleukin (IL)-1β, and (C) CD11b mRNA rose at 1 and 3 days post-injury (dpi) and were 
significantly increased at 5 dpi compared to sham-operated controls. (D) Liver CD68 mRNA increased at 1 
and 3 dpi and was increased ~3-fold at 5 dpi, but none of these changes were statistically significant (n=2). 
ANOVA p < 0.05. *p < 0.05 vs. Control, n=3/group. 
and CD11b were maximally and significantly increased at 5 days post-ligation compared to 
sham-operated controls (Fig. 1A-C).  CD68 mRNA levels were increased ~2.5-fold 
compared to sham-operated controls at 5 days post-ligation, but this change was not 
statistically significant (Fig. 1D).   This molecular data is evidence of the efficiency of this 
model to induce increased pro-inflammatory gene expression in the liver.  The 5d time 
point presents an optimal moment to induce spinal cord injury and to examine chronic 
pathological changes after both BDL and SCI such as cytokine generation.  These factors 
may then circulate in the bloodstream where they stimulate leukocyte matriculation to 
both the liver itself and the injured CNS6,10,11.   
Pro-inflammatory gene expression is upregulated after chronic cholestasis and SCI  
Previous work from our lab showed that enhanced inflammation in the liver is 
evident after spinal cord injury.  Cytokines TNFα, IL-1α, and IL-1β were all elevated 
following thoracic spinal cord injury as early as 1 dpi and as far out as 21 dpi5.  Therefore,  
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Figure 2: BDL and SCI induces chronic increases in liver pro-inflammatory gene expression. (A) Liver TNFα 
(B) IL-1β, IL-1α, CD68 and CD11b mRNA levels are elevated after BDL alone, BDL Sham + SCI and BDL + SCI at 
23 days post SCI and 28 days post-BDL. BDL alone and BDL + SCI induced the highest increases in gene 
expression.  ANOVA p < 0.05. *p < 0.05 vs. Naïve, ^p < 0.05, n=5/group. 
we next compared the effects on chronic pro-inflammatory gene expression between 
animals that received either BDL alone, BDL Sham + SCI, or BDL + SCI.  Considering that the 
expression of TNFα, IL-1β, and CD11b were all significantly increased at 5 days post-
ligation compared to sham-operated controls, we performed BDL surgery and a T8    
contusion SCI 5 days following BDL.  After 28 days post-ligation, mRNA expression of TNFα, 
IL-1β, CD68, and CD11b was significantly increased in animals that only received BDL 
surgery versus naïve animals (Fig. 2A, B, D, E).  Expression of TNFα and IL-1α were also 
significantly increased in animals that received the BDL Sham surgery + SCI at 23 days 
post-SCI compared to naïve controls (Fig. 2A, C).  This supports the results from previous 
studies in our lab that showed SCI alone causes chronic inflammation in the liver5.  The 
expression of all pro-inflammatory genes examined was significantly increased in the BDL 
+ SCI group at 23 days post-SCI and 28 days post-BDL compared to naïve animals (Fig. 2A-
E).  This indicates the two injury models compounded chronic expression of these genes in 
the liver.  mRNA expression of TNFα, IL-1β, and CD68 (Fig 2A, B, D) was also elevated 
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chronically compared to the changes seen after BDL Sham + SCI.  Inducing an enhanced 
hepatic inflammatory state after BDL and SCI—specifically due to the pro-inflammatory 
Kupffer cells, cytokines synthesized within the hepatic tissue, and enhanced leukocyte 
entry into the liver parenchyma—confirms liver injury occurring after SCI alone is 
enhanced in this paradigm. 
Bile duct ligation and spinal cord injury increase the quantity of hepatic macrophages 
 Previous data from our lab demonstrated that macrophages are increased in the 
liver within 2 h of experimental SCI and remain elevated out to 21 days post-SCI5. 
 
Figure 3: Hepatic OX42 (CD11b) immunoreactivity increased after induced chronic cholestasis and SCI. 
Representative images of OX42+ staining in the liver parenchyma from (A) Naïve, (B) BDL Sham + SCI, (C) 
BDL and (D) BDL + SCI at 23 days post-SCI and 28 days post-BDL. (E) Quantification of the hepatocyte area 
coverage of OX42+ staining. Immunoreactivity increased significantly after BDL + SCI and was unchanged 
compared to Naïve livers in the BDL and BDL + SCI animals. ANOVA p<0.05. *p<0.05, n=5-7/group.  
 
Therefore, we determined if BDL + SCI animals presented with increased Kupffer cells in 
the liver.   Kupffer cells were visualized via immunolabeling with OX42 (CD11b).  CD11b 
expression was significantly increased ~10-fold versus naïve controls in animals that 
received BDL + SCI (Fig. 3D, E).  Surprisingly, no significant changes in CD11b were seen in 
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either the BDL or BDL Sham + SCI groups compared to naïve controls (Fig. 3B, C, E).  This is 
an interesting result that differs from previous findings that show use of CD68 
immunolabeling in the liver increases ~100 fold by 21 days post-SCI5. 
 
Liver fibrosis is enhanced following BDL and SCI 
 
 In NASH pathology, accumulation of lipids by hepatic tissue leads to the propagation 
of stellate cells and irreversible fibrosis in the liver37.  Bile duct ligation-treated rats exhibit 
cholestasis, increased systemic oxidative stress, and liver fibrosis, which ultimately lead to 
liver cirrhosis.  Fibrosis is due to the proliferation of collagen-expressing hepatic stellate 
cells, typically developing 4-6 weeks after BDL in Sprague Dawley rats38.  The current study 
showed a vast upregulation of fibrotic scarring in the liver in the BDL + SCI cohort 
compared to the other experimental groups (Fig. 4A-D).  The BDL group only showed slight 
signs of increased liver fibrosis (Fig. 4C).   This suggests that performing SCI after inducing 
hepatic inflammation exacerbates and possibly expedites collagen formation and fibrosis. 
 
Figure 4: Extensive fibrosis in 
BDL + SCI livers. 
Representative images of 
Masson’s Trichrome staining 
in the liver from (A) Naïve, (B) 
BDL Sham + SCI, (C) BDL, and 
(D) BDL + SCI at 23 days post- 
SCI and 28 days post-BDL. (B) 
BDL Sham + SCI did not induce 
changes in liver 
cytoarchitecture or collagen 
deposition compared to Naïve 
livers. Beginning stages of 
collagen production and 
fibrosis were observed in (C) 
BDL livers. Advanced fibrosis 
and alteration of the liver 
cytoarchitecture were 
observed in  (D) BDL + SCI 
livers. 
 
 
Chronic cholestatic inflammation changes expression of intrahepatic lipids following SCI 
 Previous studies from our lab characterized that lipids were deposited as early as 1d 
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and maintained through 21 days post-injury after thoracic SCI5.  The presentation of fatty 
liver tissue is inherent to metabolic syndrome and NAFLD/NASH in SCI, and enhanced lipid 
accumulation in hepatic tissue was maintained chronically in these studies after all types of 
 
Figure 5: Increased lipid accumulation in the liver after BDL + SCI. Representative images of Oil Red O 
staining around vasculature in livers from (A) Naïve, (B) BDL Sham + SCI, (C) BDL, and (D) BDL + SCI at 23 
days post-SCI and 28 days post-BDL. (E) Quantification of the hepatocyte area coverage of positive lipid 
staining. Oil Red O staining increased significantly after BDL Sham + SCI and was unchanged from Naïve livers 
in the BDL and BDL + SCI animals. (F) Quantification of Oil Red O+ droplet size.  Droplet size was significantly 
increased in each group compared to Naïve and in BDL + SCI livers compared to BDL Sham + SCI and BDL 
livers.  ANOVA p<0.05. ^^p < 0.01, #p<0.05, and +++p<0.001 vs. Naïve. *p<0.05, **p<0.01, ***p<0.001, n=5-
7/group. 
injury.  The presentation of lipid retention or steatosis in the intrahepatic parenchyma is a 
hallmark of NASH pathology, and Kupffer cells aid in directing the inflammatory response 
causing hepatocyte damage and fibrosis.  This is relevant to SCI patients as this pathology is 
evident due to their excessive weight gains and elevated levels of hepatic proteins39.  Lipid 
droplet size, visualized by Oil Red O labeling, was significantly increased in all experimental 
groups over naïve controls (Fig. 5B, C, D, F), with the largest increase seen in the BDL + SCI 
group, which was ~20% larger than the BDL and BDL Sham + SCI groups.  Despite the 
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increase in lipid droplet size in the BDL + SCI group, the overall Oil Red O distribution, 
measured by percent of hepatocyte area centralized around liver vasculature, was only 
significantly increased in the BDL Sham + SCI group (Fig 5B, C, D, E).  These data support 
previous findings from our lab that showed SCI alone caused chronic increases in liver 
steatosis5.  Despite the lack of an overall change in lipid deposition, the enhanced lipid 
droplet size seen  following BDL  and SCI may contribute to the liver’s role in the acute 
phase of SCI leading to overreactivity of Kupffer cells during the hepatic acute phase 
response and pronounced intraspinal inflammation. 
Induced hepatic inflammation does not exacerbate intraspinal inflammation or lesion size  
Figure 6: Cholestasis of the common bile duct did not alter intraspinal tissue pathology after SCI.  (A, B) 
Spared white matter and (C,D) total tissue area and volumes measured via EC/NF staining were not 
significantly different between BDL Sham + SCI and BDL + SCI spinal cords at 23 days post-SCI and 28 days 
post-BDL.  (E) OX42+ immunolabeling was not significantly different between BDL Sham + SCI and BDL + SCI 
spinal cords; n=7/group. 
Liver-induced inflammation triggers disturbances in the CNS as well as metabolic 
and behavioral dysfunction12.  We hypothesized that increased liver inflammation via BDL 
before a T8 contusion SCI would exacerbate the histological deficits seen in the spinal cord 
28 days post-ligation and 23 days post-SCI.  Surprisingly, Eriochrome Cyanine staining 
revealed no significant differences in spared  white matter area and volume (Fig. 6A, B) or 
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total tissue area and volume (Fig. 6C, D) between the BDL Sham + SCI and BDL + SCI 
groups.   Thus, Kupffer cell “gain of function” via induced hepatic inflammation did not 
exacerbate the lesion size of the injured spinal cord as was expected.  Extravasation of 
hematogenous macrophages and activated resident microglia within the lesion are 
established characteristics of spinal cord injury7,40.  Immunohistochemical staining 
revealed no significant differences in OX42+ macrophages/microglia between BDL Sham + 
SCI and BDL + SCI groups (Fig. 6E).  Contrary to our predictions, no changes in secondary 
pathological events following SCI occurred when induced hepatic inflammation preceded 
spinal cord trauma. 
Gadolinium chloride selectively reduces Kupffer cells in the liver 
 
Figure 7: Intravenous GdCl3 reduces Kupffer cells.  Representative images of OX42 staining in the liver 
parenchyma from (A) Saline, (B) 10 mg/kg GdCl3, (C) 15 mg/kg GdCl3 and (D) 20 mg/kg GdCl3 48 hours after 
injection. (E) Quantifiction of OX42+ staining in the liver parenchyma. The 10 mg/kg GdCl3 dose significantly 
reduced OX42 immunoreactivity in the liver parenchyma by ~65% vs saline-injected controls. 15 mg/kg and 
20 mg/kg GdCl3 doses increased OX42+ immunoreactivity by ~35% and ~40%, respectively, compared to 
saline-injected controls.  ANOVA p<0.05. *p<0.05, **p<0.01 vs saline, n=6 for Saline and GdCl3 10 mg/kg; n=3 
for GdCl3 15 and 20 mg/kg.  
The hepatic APR contributes to the inflammation following injury to the CNS, and 
attenuating Kupffer cell activation may reduce this phenomenon8,14.  The compound 
gadolinium chloride (GdCl3) eliminates liver Kupffer cells when introduced into the 
bloodstream.  Despite the negative results of the BDL + SCI “gain of function” experiment in 
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the post-traumatic spinal cord, we hypothesize that decreasing liver inflammation before 
SCI will attenuate outcomes after SCI.  Pilot studies were conducted to determine an 
optimal dose of GdCl3 that effectively reduces Kupffer cell numbers 48 hours after lateral 
tail vein adminstration.  10mg/kg of GdCl3 reduced OX42+ cells in the liver parenchyma by 
~60% compared to saline-injected controls (Fig. 7B, E).  The 15 and 20 mg/kg doses 
surprisingly led to ~35% and ~65% increases in Kupffer cell numbers 48 hours after 
injection, indicating that these higher doses caused a robust depletion and possibly quicker, 
compensatory repopulation of Kupffer cells (Fig. 7C, D, E). None of the doses examined 
affected the numbers of OX42+ cells in the spinal cord (data not shown).  This result is 
concordant with multiple other studies attenuating insult to the liver administering this 
efficacious dose14,24,30,41.  Thus, Kupffer cell “loss of function” is achieved with GdCl3 
administration and future studies will determine if this depletion has an effect on the acute 
outcomes of SCI pathology.  
Discussion 
The current studies were designed to determine how alterations in hepatic 
inflammation affected the pathogenesis of spinal cord injury and subsequent peripheral 
sequelae.  Multiple studies demonstrate hepatic inflammation occurs prior to and facilitates 
the dramatic inflammatory response after CNS injury6,8,10,13,14,16.  Therefore, we 
investigated whether altering the hepatic acute phase response—in “gain of function” or 
“loss of function” experiments—produced any effects post-SCI.  We showed that ligation of 
the liver common biliary duct induces the production of pro-inflammatory cytokines that 
reach peak levels in the liver 5 days post-ligation.  A T8 contusive spinal cord injury during 
this peak time of liver inflammation lead to increases in chronic expression of hepatic pro-
inflammatory cytokines, Kupffer cell numbers,  fat deposition, and fibrosis compared to 
animals that either underwent BDL or SCI alone.  These pathological changes are 
concomitant with nonalcoholic fatty liver disease or NAFLD prevalent in human SCI and as 
a precedent to nonalcoholic steatohepatitis or NASH.  Despite the apparent compounding 
effect of the contused spinal cord in the already damaged liver, chronic cholestasis 
surprisingly did not lead to significant changes in spinal cord pathology compared to 
animals subjected to SCI alone.  In addition, an optimal dose of GdCl3 was established to 
selectively decrease Kupffer cell numbers in the liver parenchyma.  Future studies will 
utilize this compound with SCI to test whether downregulating the hepatic APR could 
improve post-SCI repercussions.  Understanding the inflammatory mechanisms of hepatic 
inflammation in CNS injury and vice versa could lead to therapeutic interventions in the 
future that improve clinical SCI outcomes. 
 
Preliminary experiments displayed that bile duct ligation increased hepatic pro-
inflammatory gene expression at 5 dpi.  mRNA levels were increased for TNFα and IL-1β, 
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leading credence to BDL as an effective model that induces a prolonged, sustained 
inflammatory hepatic environment28,42,43.  The hepatic APR stimulates the production of 
cytokines following trauma from multiple etiologies, and it is established that TNFα and IL-
1β are synthesized prior to later phase mediators such as IL-6 or transforming growth 
factor β (TGFβ)9.  TNFα especially is important in triggering the production of other 
mediators promoting inflammatory cell recruitment, hepatocyte death, and fibrogenesis44.  
These soluble factors are synthesized by KCs as a response to inflammatory diseases, 
increasing leukocyte number in the liver parenchyma as an initial reaction after SCI or any 
other traumatic event5,11,16.  This phenomenon was supported in our experiments as CD11b 
mRNA significantly increased 5 days post-BDL.  Marked increases in macrophage mRNA 
after BDL indicates an acute inflammatory response following hepatocellular insult.  Thus, 
pro-inflammatory gene expression was effectively elevated using BDL at 5 dpi, and it was 
concluded this was an ideal time point to use in our studies of cholestasis-induced hepatic 
inflammation and thoracic spinal contusion. 
Chronic cholestasis and SCI produces robust changes in hepatic cytokine mRNA 
synthesis, indicated by the significant increase in their transcription versus other 
experimental groups.  Previous studies show that after thoracic SCI alone, hepatic 
inflammatory cytokine mRNA of TNFα was significantly increased by 21 dpi5.  Our results 
demonstrated significant increases in TNFα, IL-1β, and CD68 transcripts 23 days after SCI 
in the BDL + SCI livers.  These findings support previous work arguing prolonged hepatic 
cytokine expression after SCI contributes to dysfunctional liver and NAFLD/NASH 
pathologies at chronic time points in models of cervical, thoracic, and lumbar SCI5.  
Cholestasis alone caused increased mRNA levels of all pro-inflammatory cytokines 
examined at 28 days post-BDL compared to naïve.  The BDL + SCI cohort yielded the 
highest expression of cytokine mRNA versus naïve and Sham + SCI animals.  This indicates 
that the upregulation of inflammatory gene transcription due to chronic cholestasis is 
exacerbated by spinal contusion, adding to the growing body of evidence arguing cross-talk 
exists between the hepatic and CNS inflammatory responses6,8,12–14.  In the BDL + SCI 
double injury model, the “cytokine storm” produced by liver Kupffer cells, stellate cells, and 
hepatocytes assists in the enhancement of leukocyte entry guiding intrahepatic 
inflammation and tissue injury.  Elevated levels of these soluble factors may also circulate 
in the bloodstream and recruit leukocytes to the injured spinal cord6,11,32.  Indeed, the 
inflammatory environment of the liver is increased in “gain of function” experiments 
indicating effects of this prolonged inflammation are detrimental to the health and lifespan 
of the SCI population.   
Liver histology experiments revealed in the BDL Sham + SCI group that hepatic 
OX42 (CD11b) immunolabeling is increased at 23 days post-SCI, again supporting the idea 
that SCI contributes to chronic hepatic inflammatory changes.   Increased OX42+ 
macrophages in livers from animals that underwent BDL before SCI indicates an increase in 
Kupffer cells and hematogenous macrophages infiltrating the liver parenchyma.  The 
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differences observed by our group in cytokine expression and influx of leukocytes to the 
liver after CNS trauma are similar to work from other groups6,13,45 and reinforces the 
argument that SCI can influence hepatic inflammatory respones.  The pathology of 
accumulating macrophages and prolonged hepatic cyokine mRNA expression further 
indicates enhanced inflammation post-SCI predisposes NAFLD/NASH-like symptoms from 
dysregulation of liver metabolism in a model of chronic liver inflammation and spinal 
contusion. The activation of pro-inflammatory Kupffer cells in NAFLD/NASH is a topic that 
is constantly being investigated.  In the fatty liver KCs are viewed as a primary source of 
cytokine and chemokine production because steatotic hepatocytes in NAFLD release 
modified lipoproteins that can activate KCs inducing an inflammatory response37.  Our 
group previously found one particular group—ceramides—increased within the liver after 
SCI.  These lipids are important signaling molecules thought to activate Toll-like receptor-4 
(TLR4) located on KCs and hepatocyes perpetuating NASH-like pathology5.  It has also been 
postulated that apoptotic hepatocytes contribute to this activation by inducing 
inflammasome complexes in liver macrophages46.  Inflammation in the NASH liver 
amplifies from various sources of lipids including accumulating free fatty acids (FFAs) in 
the circulation or endotoxins such as LPS and facilitates hepatocyte apoptosis, stimulation 
of mononuclear immune cells, and concordantly cytokine synthesis46–48.  
Hepatic fibrosis was increased and persisted chronically when experimentally 
induced hepatic inflammation preceded thoracic SCI.  Fibrosis occurs due to activation of 
hepatic stellate cells within in the space of Dissé and closely associates with the hepatic 
epithelium and sinusoidal endothelial cells49.  Hepatocellular injury induces stellate cells to 
switch from a state of quiescence to a profibrotc phenotpye.  This is in part mediated by KC 
production of cytokine TGFβ and lipid peroxides.  These products activate stellate cells and 
upregulates production of collagen, altering the cytoarchitecture of the liver32,49,50.  The 
presentation of excessive fibrosis observed in our studies potentially stems from the 
excessive cytokine synthesis, lipid deposition, and macrophage infiltration seen in the 
hepatic parenchyma and is indicative of NAFLD/NASH-like symptomatology.  In parallel 
with our KC data, this phenomenon is not uncommon as infiltration of KCs is shown to 
precede activation of stellate cells50.  Therefore, spinal cord injury conceivably enhances 
hepatic innate immune cascades leading to advanced liver pathology similar to 
NAFLD/NASH.  A plausible cause of this observation is dysfunctional fat metabolism and 
hepatocyte overload leading to macrophage accumulation, activation, and the resulting 
stellate cell-mediated fibrosis46.   
Under normal circumstances, the liver functions as a primary metabolic organ by 
producing bile.  This substance is then transferred through the biliary tree and either 
drains directly into the intestinal lumen via the common bile duct or is stored in the 
gallbladder.  Major functions of bile include the clearance of harmful endogenous or 
exogenous substances, absorption of dietary fats, and providing antibodies to fight enteric 
infections51.  Due to factors such as obesity, insulin resistance, dyslipidemia, and chronic 
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inflammation, there is strong evidence that SCI patients are more likely pre-disposed to the 
development of metabolic syndrome and NASH in the liver1,5,52.  Steatosis in the liver is 
defined as disordered lipid metabolism and accumulation triggering oxidative stress, 
inflammation, and hepatocellular damage53,54.  Following thoracic SCI, accumulation of 
lipids in hepatic tissue can be observed as early as 1 dpi and remain elevated chronically5. 
Our data show that the BDL Sham + SCI exhibited the highest overall amount of deposition, 
which supports this idea that SCI can affect hepatic lipid metabolism chronically.  
Unexpectedly however, our experiments show that lipid accumulation following 
cholestasis alone and cholestasis followed by SCI is unchanged compared to naïve controls.   
These results are surprising based on previous studies displaying a direct 
correlation between increased hepatic inflammation and lipid deposition5.  This 
phenomenon may be due to the beginning signs of fibrosis seen in the BDL group and 
extensive fibrosis post-BDL + SCI.  Nevertheless, our results still indicate disruption of 
metabolic homeostasis in the liver influences the vast accumulation of lipids observed in 
NAFLD/NASH occurring after chronic SCI5,46,53.  Despite the BDL + SCI cohort showing 
unchanged overall lipid deposition compared to naïve controls, significantly larger lipid 
droplet sizes were observed when juxtaposed to BDL and Sham + SCI cohorts.  A 
characteristic of steatosis in the liver is the presence of lipid droplets.  Initially viewed only 
as inert fat storage, lipid droplets are increasingly being recognized as functional cellular 
organelles consisting of regulatory proteins utilized for cell signaling, lipid metabolism, and 
inflammation54–56.  These cellular constituents are possibly concomitant with regulating 
transcriptional control of inflammation, supplementing KC activation and macrophage 
recruitment.  It is speculated certain components within lipid droplets have the capability 
to activate KCs in fatty liver diseases; however, this has never been directly tested54.   
 
Injury to spinal cord inhibits the direct line of CNS communication to the periphery 
originating from pre-ganglionic sympathetic neurons in the intermediolateral cell column 
or descending parasympathetic pathways22 and leads to improper communication and 
dysfunction.  Autonomic regulation of the liver is dysfunctional after SCI, and the liver 
undergoes severe changes including upregulation of leukocytes and chronic pro-
inflammatory cytokine synthesis, steatosis, and fibrosis as a result.  Though the 
endogenous neuroinflammatory response after SCI is substantial, multiple reports indicate 
a hepatic inflammatory component precedes intraspinal inflammation and may promote 
recruitment of peripheral monocytes to the site of injury6,8,11,16,20.  It was postulated that 
upregulating liver inflammation prior to spinal contusion would elevate inflammation after 
SCI and in turn exacerbate damage in the spinal cord.  However, there were no discernable 
differences in spared total tissue or spared white matter tissue between the Sham + SCI and 
BDL + SCI cohorts.  We also demonstrated that hepatic APR “gain of function” experiments 
did not change expression of macrophages/microglia in the spinal cord lesion epicenter.  
The influx of hematogenous leukocytes and microglial activation contribute to destruction 
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of the blood-spinal cord barrier and secondary tissue damage observed after traumatic 
SCI7,18,57.  Removal of hematogenous macrophages from the lesion epicenter showed 
promise in previous work as a therapeutic intervention58.  Other studies using bone 
marrow chimeric mice showed peripheral leukocyte entry into the contused spinal cord 
occurs40 maximally at 7 dpi18.  The current findings suggest no significant pathological 
changes in the lesion occur if hepatic inflammation precedes spinal cord injury. 
The BDL model itself potentially is the culprit behind the unexpected lack of altered 
spinal cord pathology in the BDL + SCI group.  It is important to remember the hepatic APR 
contributes to and possibly precedes intraspinal pathology, but there is still an endogenous 
SCI inflammatory cascade predominating at the site of the lesion6,57.  The BDL surgery is 
effective at increasing inflammation in the liver, yet the downside is the severe pathological 
changes that it induces in the liver, such as advanced fibrosis, which could be impacting 
liver function at an extreme level.   Future studies will be needed to elucidate an alternative 
model that targets inflammatory cells while also limiting the amount of stellate cell 
activation and subsequent liver fibrosis.  Two options include using either a shorter BDL 
time point than 28 days or to employ a reversible BDL model59.  Fibrosis typically forms in 
livers anywhere from 14 to 28 days following BDL.  Utilizing a shorter time point or a 
reversible BDL model could eliminate any confounds the advanced fat deposition and 
fibrosis create while still taking advantage of the inflamed liver environment.  One group 
also reported an effective murine model for acute hepatitis B that subsides after 7 days 
post-injection via tail vein60.  Transfection with this type of acute virus could provide a 
suitable inflammatory response in the liver that may enhance the APR after SCI.  If 
alternative methods do not elicit exacerbated SCI pathology, it could reveal that the hepatic 
APR reaches a threshold contribution following CNS injury.  Essentially this means the liver 
differentially contributes to the secondary damage occurring after SCI when compared to 
the endogenous spinal cord response.  Even so, this does not indicate the hepatic APR is 
devoid of a role in the cascade of neuroinflammatory events after SCI. 
 
The Kupffer cell reducing compound GdCl3 decreased hepatic parenchymal 
macrophages 48 hours after IV injection at an optimal dose of 10 mg/kg.  This preliminary 
finding indicates significant KC knockdown in the liver is possible, yet further analysis of 
hepatic cytokine gene expression and histological consequences are required.  Future 
experiments will couple SCI at 48 hours after GdCl3 injection to analyze the effect of KC 
depletion on the lesion in the spinal cord and resulting pathology in the liver.  Recent 
studies reveal that Kupffer cell knockdown prior to SCI reduced neutrophils recruited to 
the contused spinal cord by ~50% using clodronate liposomes8.  Reducing KC numbers 
using this same technique also proved to reverse hepatic steatosis and macrophage 
recruitment in the NASH liver47.  Therefore, it can be said that targeting this specific cell 
population may potentially reduce the inflammatory response in the injured CNS and 
reduce secondary damage as a result of this attenuation.  KC knockdown may also quell 
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fibrosis in the liver as these cells are important synthesizers of pro-fibrotic factors like 
TGFβ and facilitate activation of hepatic stellate cells32.  By inhibiting KC responses, the 
vicious cycle perpetuating liver damage and inflammation after spinal cord injury could be 
inhibited and lead to therapeutic improvements. 
   
 Altered peripheral outcomes of traumatic SCI ensue after chronic cholestasis and 
thoracic spinal contusion in rat models.  The array of changes in pro-inflammatory cytokine 
gene expression, macrophage expression, lipid accumulation, and fibrosis in the liver 
contribute further evidence to the concept of hepatic inflammation preceding and 
exacerbating peripheral damage after intraspinal trauma.  These findings supplement 
previous work revealing SCI leads to symptoms concomitant with nonalcoholic 
steatohepatitis, a chronic health condition due to metabolic syndrome in clinical cases.  
Although spinal cord pathology was not altered by cholestasis-induced hepatic 
inflammation, further analyses will need to be carried out to determine if augmenting 
hepatic inflammation prior to SCI influences post-traumatic after effects.  Attenuation of 
macrophage levels in the liver parenchyma reveals the exciting potential to improve 
outcomes following experimental SCI.  A physiologically important metabolic and 
immunological organ, the liver is a fascinating therapeutic target to study.  Diminishing its 
role as both victim and malefactor of CNS injury may improve quality of life, health, and 
well-being in future clinical cases of human SCI. 
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